Table 1.
Chemistry | Compounds | HDAC Targets | Clinical trials | Ref |
---|---|---|---|---|
Hydroxymates | SAHA (vorinostat) | Classes I, II, and IV | Phase III* | [6] |
PXD101 (belinostat) | Classes I, and IIa, HDAC6 | Phase II | [7] | |
Trichostatin A | Classes I and II | Toxic | [8] | |
LAQ824 (dacinostat) | Classes I and II | Phase I | [9] | |
PCI24781 | Classes I and IIb | Phase I | [10] | |
LBH589 (panobinostat) | Classes I and IIa | Phase II | [11] | |
Cyclic tetrapeptides | FK228 (romidepsin) | HDAC1, 2, 4, 6 | Phase II | [12] |
Benzamides | MGCD0103 (mocetinostat) | HDAC1, 2, 3, 11 | Phase II | [13] |
MS275 (entinostat) | HDAC1, 2, 3, 9 | Phase II | [14] | |
Short-chain fatty acids | Valproic acid | Classes I and IIa | Phase II | [15] |
Butyrate | Classes I and IIa | Phase II | [16] |
*Approved (cutaneous T-cell lymphoma).